Recent developments in molecular profiling of bladder cancer

Current Opinion in Urology

Volumn 16, Issue 5, 2006, Pages 377-381

  Ørntoft, Torben F ^a   Zieger, Karsten ^a   Dyrskjøt, Lars ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Genomic instability; Microarrays; Molecular profiling; Predictive cancer markers; Transcriptome

Indexed keywords

TRANSCRIPTOME;

BLADDER CANCER; CANCER INVASION; CANCER STAGING; CARCINOMA IN SITU; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

CARCINOMA IN SITU; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 33747191454     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mou.0000240313.16324.d3     Document Type: Review

References (14)

1. Dyrskjøt L, Thykjaer T, Kruhoffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003; 33:90-96.
2. Kim JH, Tuziak T, Hu L, et al. Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Lab Invest 2005; 85:532-549. A profound study of markers for the different pathways of bladder cancer.
3. Blaveri E, Brewer JL, Roydasgupta R, et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005; 11 (19 Pt 1):7012-7022.
4. Wild PJ, Herr A, Wissmann C, et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 2005; 11:4415-4429. To our knowledge, the only profiling study of bladder cancer that use micro-dissected tissue specimens.
5. Aaboe M, Marcussen N, Jensen KM, et al. Gene expression profiling of noninvasive primary urothelial tumours using microarrays. Br J Cancer 2005; 93:1182-1190.
6. Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54:784-788.
7. Zieger K, Dyrskjøt L, Wiuf C, et al. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res 2005; 11:7709-7719. First paper to relate FGFR3 mutation and the occurrence of CIS to genomic instability.
8. Dyrskjøt L, Zieger K, Kruhoffer M, et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 2005; 11:4029-4036. A large clinical study showing the use of different end-points in combination with microarray profiling.
9. Primdahl H, Wikman FP, von der Maase H, et al. Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays. J Natl Cancer Inst 2002; 94:216-223.
10. Thykjaer T, Workman C, Kruhoffer M, et al. Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Res 2001; 61:2492-2499.
11. Blaveri E, Simko JP, Korkola JE, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005; 11:4044-4055.
12. Modlich O, Prisack HB, Pitschke G, et al. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res 2004; 10:3410-3421.
13. Sanchez-Carbayo M, Socci ND, Lozano J, et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006; 24:778-789. Large study on invasive tumors identifying potential poor outcome markers.
14. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005; 11:2625-2636.